Cosmo: Strong growth of key products to continue into 2026

Tuesday, March 10, 2026 @ 12:00 am

Cosmo announced FY 2025 results: revenue met guidance, while EBITDA and the year-end cash position exceeded guidance, driven by GI Genius and Winlevi, confirming operating leverage as scale builds. For FY 2026, strong double-digit growth in recurring revenue and EBITDA is expected.

Key catalysts include:

1. Clascoterone 5% 12-month safety & efficacy data (spring 2026)
2. Winlevi EU commercial launch by partners (H1 2026)
3. CB-03-10/cortexelone potential partnering (H2 2026)

Key catalysts include:

1. Clascoterone 5% 12-month safety & efficacy data (spring 2026)
2. Winlevi EU commercial launch by partners (H1 2026)
3. CB-03-10/cortexelone potential partnering (H2 2026)

Cosmo Flash Update

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

MetrioPharm appoints Steffen Stürzebecher as chief medical officer

Steffen Stürzebecher, MD, PhD, takes on the position of Chief Medical Officer (CMO). He joins the management team of Thomas Christély, CEO, and Marcus Thelen, PhD, CSO.
March 11, 2026

BioLizard wins 2025 BioTech Breakthrough Award for “Bioinformatics Innovation of the Year”

BioLizard has been named “Bioinformatics Innovation of the Year” in the 2025 BioTech Breakthrough Awards. The honor spotlights Bio|Verse Navigator, a visual analytics workspace that unifies complex R&D data so scientists can decide faster, with confidence.
March 6, 2026

Pharvaris: Data supporting treatment of bradykinin-mediated angioedema

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and confirming its potentially differentiated profile for the treatment of HAE attacks Final CHAPTER-1 data provide further evidence on long-term safety and efficacy of deucrictibant fo
March 2, 2026

Helsinn Healthcare & InVirtuoLabs: Collaboration in AI-driven drug discovery

Helsinn Healthcare SA (Helsinn), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and In Virtuo Laboratories SA (InVirtuoLabs), a Lugano-based drug discovery company specializing in AI-powered generative chemistry, today announced a strategic collaboration to discover and develop novel small-molecule therapeutics.
February 25, 2026

Medistri becomes member of Swiss Medtech

Medistri, a provider of contract sterilization, laboratory, packaging validation, manufacturing, logistics, and consulting services for the healthcare industry, has become a member of Swiss Medtech, the association representing the Swiss MedTech sector.
February 24, 2026